INsTRuCT Consortium

INsTRuCT is an Innovative Training Network (ITN) funded by the European Union Horizon 2020 Programme. The INsTRuCT Consortium is a research network of leading European scientists from academia and industry focused on fundamental research and clinical translation of myeloid regulatory cell (MRC)-based immunotherapies. A total of 15 doctoral research projects (PhD projects) for Early Stage Researchers (ESR) are offered across 13 institutes in Europe. Research topics range from fundamental to translational science, all at the forefront in the field of MRC-based immunotherapies. Successful applicants will also receive expert training in basic immunological research, preclinical pharmacological development, manufacturing processes, clinical trial design, healthcare economics, ethics and marketing. The interaction of biologists, computational scientists, physicians and engineers is central to INsTRuCT and will challenge ESR to explore complex issues in bench-to-bedside research from different perspectives. Graduates of INsTRuCT will be well-prepared to enter the workplace with an innovative and beyond state-of-the-art view on fundamental and translational science of cell-based therapies that will accelerate the future of the field.

Participating in INsTRuCT offers early stage researchers many unique opportunities, including:

• A project as Marie Skłodowska Curie trainee in one of the participating institutions with the intention of receiving a doctoral degree (PhD).
• State-of-the art, exciting research in an international consortium with highly integrated research projects.
• Expert training in preclinical and clinical development of cell-based medicinal products.
• At least two months of research training in the lab of another consortium member, mostly in a different EU country than the country where most of the project will take place.
• Training in both academic and commercial research environments.
• Salary according to EU guidelines for Marie Skłodowska Curie trainees, including mobility payments and family allowances where applicable.

Eligible candidates must:

• hold a Master’s degree or equivalent in a field of science relevant to their chosen project (see below)
• demonstrate a history of academic excellence
• demonstrate an affinity for Basic Immunology, Computational Biology, bio(medical / process) engineering or translational research
• speak and write fluently in English
• have less than 4 years’ previous research experience and not hold a doctoral (PhD) title
• have not been resident in the country where the host institution is located for more than 12 months in the 3 years before recruitment.
• be available for a personal interview at the INsTRuCT recruitment meeting in Barcelona, 23rd-25th March 2020.
• be available to start their project no later than 1st September, 2020.

www.instruct-h2020.eu
INsTRuCT will select ESR through a 2-step recruitment process. Candidates should submit their application for their top two or three preferred research projects. Applications (in English) should include a CV, a Letter of Motivation and a Letter of Recommendation from two appropriate referees. **The closing date for applications is January 31st, 2020.** Application documents should be sent by email to Mrs. Christine Bayer, Project Administrator (christine.bayer@ukr.de) and the relevant project supervisors by email (see individual project descriptions). Applicants are advised to familiarise themselves thoroughly with projects for which they apply and be ready to answer questions on their chosen topics. After reviewing all project applications, supervisors of individual projects will contact selected applicants to organise an initial screening interview by telephone or videoconferencing. The most promising candidates will then be invited to a personal interview in a recruitment meeting of the whole consortium in Barcelona on **23rd - 25th March, 2020.** Approximately half of those interviewed in the second round will be offered a position.

### Research projects offered by INsTRuCT

<table>
<thead>
<tr>
<th>ESR</th>
<th>Project Title</th>
<th>Subject Area</th>
<th>Primary Supervisor</th>
<th>Institution</th>
<th>EU State</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Metabolic Programming of Human Monocyte Differentiation</td>
<td>Molecular Immunology</td>
<td>ZASLONA, Z. <a href="mailto:zaslonaz@tcd.ie">zaslonaz@tcd.ie</a></td>
<td>Trinity College Dublin</td>
<td>IE</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial and metabolic functions of tolerogenic myeloid cells</td>
<td>Molecular Immunology</td>
<td>SAWITZKI, B. <a href="mailto:birgit.sawitzki@charite.de">birgit.sawitzki@charite.de</a></td>
<td>Berlin Charité</td>
<td>DE</td>
</tr>
<tr>
<td>3</td>
<td>Engineered Tolerogenic Dendritic Cells for Ag-Specific Immunotherapy</td>
<td>Molecular Immunology</td>
<td>GREGORI, S. <a href="mailto:silvia.gregori@hsr.it">silvia.gregori@hsr.it</a></td>
<td>Ospedale San Raffaele</td>
<td>IT</td>
</tr>
<tr>
<td>4</td>
<td>Trained Immunity in Regulatory Macrophages</td>
<td>Molecular Immunology</td>
<td>OCHANDO, J. <a href="mailto:jordi.ochando@msm.edu">jordi.ochando@msm.edu</a></td>
<td>University of Madrid</td>
<td>ES</td>
</tr>
<tr>
<td>5</td>
<td>A data science approach to characterising myeloid regulatory cell therapies</td>
<td>Computational Biology</td>
<td>LORD, P. - HILKENS, C. <a href="mailto:phillip.lord@newcastle.ac.uk">phillip.lord@newcastle.ac.uk</a>, <a href="mailto:cathar.en.hilkens@newcastle.ac.uk">cathar.en.hilkens@newcastle.ac.uk</a></td>
<td>University of Newcastle</td>
<td>GB</td>
</tr>
<tr>
<td>6</td>
<td>Investigating molecular mechanisms of human autologous tolerogenic DC</td>
<td>Cellular Biology</td>
<td>MOREAU, A. <a href="mailto:aurele.moreau@univ-nantes.fr">aurele.moreau@univ-nantes.fr</a></td>
<td>University of Nantes</td>
<td>FR</td>
</tr>
<tr>
<td>7</td>
<td>Signatures of tolerogenic cell products in vivo and in vitro</td>
<td>Computational Biology</td>
<td>REHLI, M. - SPANG, R. <a href="mailto:michael.rehli@ukr.de">michael.rehli@ukr.de</a>, <a href="mailto:rainer.spang@ukr.de">rainer.spang@ukr.de</a></td>
<td>University Hospital Regensburg</td>
<td>DE</td>
</tr>
<tr>
<td>8</td>
<td>Development of Pharmaceutical Release Processes for DC-based Therapy</td>
<td>GMP Manufacturing</td>
<td>GERMERAAD, W. <a href="mailto:w.germeraad@cimaas.com">w.germeraad@cimaas.com</a></td>
<td>Cimaas BV</td>
<td>NL</td>
</tr>
<tr>
<td>9</td>
<td>Personalized MRC-based therapy: Innovative strategies to improve efficacy</td>
<td>Computational Biology</td>
<td>SANCHEZ FUEYO, A. <a href="mailto:sanchez_fueyo@kcl.ac.uk">sanchez_fueyo@kcl.ac.uk</a>, <a href="mailto:giovanna.lombardi@kcl.ac.uk">giovanna.lombardi@kcl.ac.uk</a></td>
<td>King’s College London</td>
<td>GB</td>
</tr>
<tr>
<td>10</td>
<td>Development and validation of antigen-specific assays for T and B cell responses</td>
<td>Cellular Immunology</td>
<td>BRINKE, A. - van HAM, M. <a href="mailto:a.tenbrinke@sanquin.nl">a.tenbrinke@sanquin.nl</a>, <a href="mailto:m.vanham@sanquin.nl">m.vanham@sanquin.nl</a></td>
<td>Sanquin Blood Supply and University of Amsterdam</td>
<td>NL</td>
</tr>
<tr>
<td>11</td>
<td>Development of an affordable &amp; scalable process for tolDC manufacturing</td>
<td>GMP Manufacturing</td>
<td>COOLS, N. <a href="mailto:Nathalie.Cools@uze.be">Nathalie.Cools@uze.be</a></td>
<td>University of Antwerp</td>
<td>BE</td>
</tr>
<tr>
<td>12</td>
<td>Classification of Human Myeloid Regulatory Cell Networks by Machine Learning</td>
<td>Computational Biology</td>
<td>KOLLET, J. <a href="mailto:jutta.kollett@miltenyibiotec.de">jutta.kollett@miltenyibiotec.de</a></td>
<td>Miltenyi Biotec BV &amp; Co. KG</td>
<td>DE</td>
</tr>
<tr>
<td>13</td>
<td>Genes &amp; pathways associated with the tolerogenic capacity of tolDC-VITD3</td>
<td>Molecular Immunology</td>
<td>MARTINEZ, E. <a href="mailto:emmartinez.germanistras@gencat.cat">emmartinez.germanistras@gencat.cat</a></td>
<td>Institute of the Germans Trias i Pujol Foundation</td>
<td>ES</td>
</tr>
<tr>
<td>14</td>
<td>Human Mreg-mediated conversion of naïve CD4+ T cells to iTreg</td>
<td>Cellular Immunology</td>
<td>HUTCHINSON, J. <a href="mailto:james.hutchinson@ukr.de">james.hutchinson@ukr.de</a></td>
<td>University Hospital Regensburg</td>
<td>DE</td>
</tr>
<tr>
<td>15</td>
<td>Route of delivery of tolerogenic dendritic cells</td>
<td>Clinical Immunology</td>
<td>HILKENS, C. <a href="mailto:john.isaac@newcastle.ac.uk">john.isaac@newcastle.ac.uk</a>, <a href="mailto:cathar.en.hilkens@newcastle.ac.uk">cathar.en.hilkens@newcastle.ac.uk</a></td>
<td>University of Newcastle</td>
<td>GB</td>
</tr>
</tbody>
</table>
Further Information

Interested candidates are advised to visit the INsTRuCT Consortium website for further information about projects. Questions about recruitment, training opportunities and the scientific activities of the INsTRuCT Consortium should be directed to Dr. James Hutchinson, Project Coordinator. INsTRuCT is committed to a fair, open, transparent and merit-based recruitment of researchers. To comply with Research Executive Agency policy, the INsTRuCT Consortium will retain copies of all documents submitted by all applicants at least until completion of the Project. In addition, INsTRuCT will retain copies of all evaluations made by project supervisors at every stage of the recruitment process. By submitting their application to INsTRuCT, candidates agree to their personal data being kept on record by University Hospital Regensburg and communicated to EU officials if demanded. The Data Protection Officer (DPO) at University Hospital Regensburg is Dr. Wolfgang Börner, who can be contacted by telephone on +49-(0)941 944 4420 or by sending an email to dsb@ukr.de.

www.instruct-h2020.eu
**ESR1**
**Metabolic Programming of Human Monocyte Differentiation**

<table>
<thead>
<tr>
<th>Host Institution</th>
<th>Trinity College Dublin, Ireland</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Supervisor</td>
<td>Dr. ZASLONA, Zbignew</td>
</tr>
<tr>
<td>Email address</td>
<td><a href="mailto:zaslonaz@tcd.ie">zaslonaz@tcd.ie</a></td>
</tr>
<tr>
<td>Planned duration</td>
<td>36 months</td>
</tr>
<tr>
<td>Subject Area</td>
<td>Molecular Immunology; Cellular Metabolism</td>
</tr>
</tbody>
</table>

**Introduction:** After emigrating from the blood to tissues, monocytes continue their maturation and undergo final differentiation into long-lived tissue-specific macrophages. **Immune-metabolites, such as succinate and itaconate, markedly influence monocyte-to-macrophage transition and functional polarisation;** however, we do not fully understand the mechanistic links between these metabolites and macrophage differentiation. A deeper appreciation of metabolic control of macrophage polarisation will lead to superior MRC-based therapies.

**Aims:**

A1: We will assess how immunometabolites affect monocyte-to-macrophage differentiation using in vitro systems;  
A2: We will study the effects of immune-metabolites on monocyte recruitment and differentiation into macrophages in a mouse model of LPS-induced peritonitis.  
A3: In an OVA-induced murine asthma model, macrophages accumulate by local proliferation. We will explore how this process is affected by succinate and itaconate.

**Expected Results:**

R1: The role of succinate and itaconate in regulation of monocyte differentiation and macrophage maturation will be elucidated.  
R2: We will define mechanisms by which these immunometabolites affect the process of monocyte recruitment and macrophage proliferation in vivo. Since succinate and itaconate production is altered by disease states, and because maturation status influences macrophage functions, our findings will have broad clinical implications.

**Planned secondment:**

(1) An international 3-month secondment to Regensburg, Germany is planned as a networking, technical and scientific exchange.  
(2) An international, intersectoral 3-month secondment to GSK is planned, giving the ESR an opportunity to work with diseased human material.

**Enrolment in Doctoral degree(s):** Trinity College Dublin

**Project-specific selection criteria:** Desirable experience in molecular biology laboratory, preferable experience with techniques, such as Western Blotting, flow cytometry and qPCR. Knowledge of Immunology and in particular innate immunity preferable.

**Recommended reading:**

**ESR2**

Mitochondrial and metabolic functions of tolerogenic myeloid cells

<table>
<thead>
<tr>
<th>Host Institution</th>
<th>Charité University Hospital, Berlin, Germany</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Supervisor</td>
<td>Prof. SAWITZKI, Birgit</td>
</tr>
<tr>
<td>Email address</td>
<td><a href="mailto:birgit.sawitzki@charite.de">birgit.sawitzki@charite.de</a></td>
</tr>
<tr>
<td>Planned duration</td>
<td>36 months</td>
</tr>
<tr>
<td>Subject Area</td>
<td>Molecular Immunology; Cellular Metabolism</td>
</tr>
</tbody>
</table>

**Introduction:** Recent evidence indicates that mitochondrial function controls macrophage and DC activity. By regulating substrates for histone acetylation and methylation, cellular metabolism controls transcription through epigenetic mechanisms. Mitochondrial dynamics control metabolic programming, hence immune cell differentiation. We hypothesise that mitochondrial fission underlies the shift towards glycolysis and inflammatory phenotype in DCs and macrophages, whereas enforced mitochondrial fusion maintains a stable regulatory phenotype. Our work suggests innovative approaches for developing more stable MRC that could be used as safer or more potent cell-based immunotherapies.

**Aims:**

- **A1:** To study mitochondrial dynamics, function and cellular metabolism in various MRC populations, including DC10, Tol-DC, ATDC and Mregs.
- **A2:** To explore the possibility of interfering with proteins regulating mitochondrial dynamics to generate more stable MRC.

**Expected Results:**

- **R1:** Characterising mitochondrial functions and cellular metabolism of different MRC subtypes will lead to a more complete scientific understanding of their interrelationships;
- **R2:** This work will determine whether a stable, maturation-resistant phenotype in MRC is dependent upon fusion-like morphology of mitochondria and their oxidative phosphorylation activity;
- **R3:** Small molecule inhibitors and genetic engineering will be used to reinforce mitochondrial fusion in MRC products;
- **R4:** As a pharmacodynamic indicator, immune monitoring methods will be implemented to analyse mitochondrial morphology and functions following in vivo transfer of MRC.

**Planned secondment:** An international, intersectoral 3-month secondment to Sanofi is planned to support preclinical development of gene therapy approaches to stabilising MRC function.

**Enrolment in Doctoral degree(s):** Charité University Hospital, Berlin

**Project-specific selection criteria:** Experience with primary cell culture, flow cytometry and an interest in bioinformatics / R programming

**Recommended reading:**

**ESR3**  
**Engineered Tolerogenic Dendritic Cells for Ag-Specific Immunotherapy**

<table>
<thead>
<tr>
<th>Host Institution</th>
<th>Ospedale San Raffaele, Milan, Italy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Supervisor</td>
<td>Dr. GREGORI, Silvia</td>
</tr>
<tr>
<td>Email address</td>
<td><a href="mailto:silvia.gregori@hsr.it">silvia.gregori@hsr.it</a></td>
</tr>
<tr>
<td>Planned duration</td>
<td>36 months</td>
</tr>
<tr>
<td>Subject Area</td>
<td>Molecular &amp; Cellular Immunology; Epigenomics</td>
</tr>
</tbody>
</table>

**Introduction:** DC-10 is a promising example of tolDC-based cell therapy, representing a subset of DC that spontaneously releases IL-10 and induces Ag-specific T regulatory cells (Tregs). This project pursues an innovative strategy for engineering a more stable and potent MRC-based therapy. Forced over-expression of IL-10 and nominal antigens in genetically engineered DC using state-of-the-art lentiviral vector (LV) technology allows us to generate functionally stable human DC (known as IL-10-tolDC) that suppress antigen-specific Teff cells and promote antigen-specific Tregs.

**Aims:**  
**A1:** To define in vitro stability and in vivo biodistribution of IL-10-tolDC;  
**A2:** To investigate the tolerogenic potential of IL-10-tolDC, their mode of action and ability to promote/restore tolerance in vitro and in pre-clinical models;  
**A3:** To define the genetic/epigenetic landscape of IL-10-tolDC.

**Expected Results:**  
**R1:** Characterization of IL-10-tolDC bio-distribution, stability, survival, and function in pre-clinical models;  
**R2:** Preclinical development of a IL-10-tolDC-based cell therapy;  
**R3:** Better understanding of the molecular mechanisms underlying regulatory DC biology and identification of targetable pathways to boost IL-10-mediated tolerance.

**Planned secondment:** (1) An international 2-month secondment to Prof. Jordi Ochando’s lab is planned as a networking, technical and scientific exchange. (2) An international, intersectoral 2-month secondment to Cimaas BV is planned to support preclinical development of gene therapy approaches to stabilizing MRC function.

**Enrolment in Doctoral degree(s):** University Vita Salute

**Project-specific selection criteria:** Degree in Biological Sciences, Biotechnology or related disciplines with skills in molecular and cellular biology as well as primary human cell culture and manipulation. The use of FACS/sorter and experience in animal handling is a significant plus.

**Recommended reading:**  
Introduction: The innate immune system displays long-term changes in its functional capacities through epigenetic programming of macrophages and monocytes, a phenomenon known as ‘trained immunity.’ Trained immunity is likely to be a critical issue in MRC-based therapy, affecting the quality of therapeutic cell products, their functional stability and their effects in patients. This project concerns an innovative treatment paradigm in which innate immune cells are specifically targeted and “untrained” using drug-loaded nanobiologics. A trained immunity-inhibiting nanobiologic library of high-density lipoprotein (HDL) derived nanomaterials with different immunomodulatory payloads will be created using advanced microfluidics technology. These highly innovation nanobiologics will complement future cell-based therapeutic approaches, both in terms of producing superior MRC-based products and co-treatment of patients receiving MRC-based therapies.

Aims: A1: To develop nanobiologic library technology to regulate trained immunity; A2: To evaluate the robustness of our trained immunity-inhibitory nanobiologics to prevent organ transplant rejection; A3: To test trained immunity-inhibitory nanobiologics as substances added to cell cultures during manufacture of MRC-based therapeutic products.

Expected Results: R1: Development of optimized nanoformulations that target different molecular pathways associated with trained immunity. This program’s successful completion will yield targeted immunotherapies not only to potentially treat transplant patients, but also autoimmune disorders and allergies.

Planned secondment: An international, intersectoral 6-month secondment to the non-academic group of Dr. Gregori (OSR, M22) is planned to support preclinical development of gene therapy approaches to stabilising MRC function.

Enrolment in Doctoral degree(s): Complutense University of Madrid

Project-specific selection criteria: Practical experience of common techniques in Molecular Biology and Cellular Immunology.

**ESR5**

**A data science approach to characterising tolerogenic myeloid regulatory cell therapies in a standardised manner**

<table>
<thead>
<tr>
<th>Host Institution</th>
<th>Newcastle University, United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Supervisor</td>
<td>Dr. LORD, Phillip (primary) Dr. HILKENS, Catharien</td>
</tr>
<tr>
<td>Email address</td>
<td><a href="mailto:phillip.lord@newcastle.ac.uk">phillip.lord@newcastle.ac.uk</a> - <a href="mailto:catharien.hilkens@newcastle.ac.uk">catharien.hilkens@newcastle.ac.uk</a></td>
</tr>
<tr>
<td>Planned duration</td>
<td>36 months</td>
</tr>
<tr>
<td>Subject Area</td>
<td>Computational Biology; Data Science</td>
</tr>
</tbody>
</table>

**Introduction:** Basic and translational research in immunoregulatory cell-based therapy has been limited by the intrinsically small-scale of clinical trials, which hampers comparison, standardization and reproducibility. Our group has spearheaded initiatives to define reporting guidelines for cell-based therapies, which serve as a foundation for further standardization efforts. This project aims to combine data from consortium partners with publically available knowledge to achieve two main goals: firstly, to unify descriptions of the pharmacological properties of tolerogenic cell products in order to support standardisation of their quality-control; secondly, to predict the immune regulatory effects of tolerogenic cell products, which will inform the design of standardised immunomonitoring in clinical trials.

**Aims:**

**A1:** To build a warehouse of publically available data on tolerogenic cell therapies and incorporating relevant background resources, including pathway, cell development and pharmacological data sets.

**A2:** To embed good data management practice, enabling reproducibility and data sharing as the default behaviour within the consortium.

**A3:** To enable semantic descriptions to cell products and immunomonitoring read-outs.

**A4:** To predict optimal strategies for quality-control and immunomonitoring by using a combination of semantic similarity, rule-based learning and other computational learning techniques.

**Expected Results:** This research provides an innovative solution for predicting the immune regulatory effects of tolerogenic MRC-based products by creating an integrated, big data set scale through standardisation and data warehousing. **R1:** The proposed ‘data warehouse’ will represent a major scientific output of this project, which will be an extremely value resource for INsTRuCT partners and the wider field. **R2:** Development of recommendations about quality-control testing of MRC products; **R3:** Development of recommendations about the optimal conditions for ex vivo generation of MRC products.

**Planned secondment:**

1. 3-month secondment to SciBite (Cambridge, UK, M18) to learn new tools for the curation and management of biomedical data.
2. An international, 2-month secondment to Prof. Nathalie Cools’ lab to learn about new GMP-compliant technologies and regulations for manufacturing of MRC-based products.

**Enrolment in Doctoral degree(s):** Newcastle University

**Project-specific selection criteria:** As this is a cross-disciplinary project, a Masters degree or equivalent in bioinformatics, or computational biology is preferable. Also acceptable, a BSc or equivalent in Computing Science, a BioMedical Science (inc. Immunology), with a strong and demonstrable interest in the other discipline. Experience with (some of) knowledge representation, biological data handling, databases or data integration.

**Recommended reading:**

**ESR6**

**Investigating molecular mechanisms of human autologous tolerogenic DC**

<table>
<thead>
<tr>
<th>Host Institution</th>
<th>University of Nantes, France</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Supervisor</td>
<td>Dr. MOREAU, Aurélie</td>
</tr>
<tr>
<td>Email address</td>
<td><a href="mailto:aurelie.moreau@univ-nantes.fr">aurelie.moreau@univ-nantes.fr</a></td>
</tr>
<tr>
<td>Planned duration</td>
<td>36 months</td>
</tr>
<tr>
<td>Subject Area</td>
<td>Molecular &amp; Cellular Immunology; Cellular Metabolism</td>
</tr>
</tbody>
</table>

**Introduction:** Autologous Tolerogenic Dendritic Cells (ATDC) exhibit tolerogenic properties in vitro and in vivo. Human ATDCs are currently being investigated in a Phase I/II clinical trial in kidney transplantation. ATDC produce high levels of lactate that steer T cell responses towards tolerance. This project concerns further investigation of molecular mechanisms of ATDC action using cutting-edge techniques in order to develop of innovative methods for quantifying therapeutic effects of ATDC in solid organ transplant recipients.

**Aims:**

**A1:** To examine the phenotypic and functional heterogeneity of ATDC by single cell RNASeq and epigenetic profiling studies.  

**A2:** Using LV coding for shRNA, we will delete molecules thought to be relevant to the regulatory function or stability of ATDCs. Gene-edited ATDCs will then be examined in vitro and in vivo using established assays and animal models.  

**A3:** The utility of functionally important molecules as biomarkers of ATDC effects in vivo will be explored using archived blood samples from patients treated with ATDCs or other immune regulatory cells.

**Expected Results:**

**R1:** Understanding of the molecular mechanisms of ATDC action, allowing us to systematically compare ATDC function with other MRC products.  

**R2:** Novel molecules contributing to ATDC action will be mechanistically investigated.  

**R3:** Innovative tests for ATDC pharmacodynamic effects will be developed, standardised and clinically validated.

**Planned secondment:**

1. An intersectoral secondment of 2-months to Immunotech which produces CE/IVD-marked reagents and assays.  
2. A 2-month intersectoral secondment to Silvia Gregori’s lab is critical to aim A1.

**Enrolment in Doctoral degree(s):** University of Nantes

**Project-specific selection criteria:** Master degree in Science, strong knowledge in immunology and experience with (or interest for) bioinformatic tools.

**Recommended reading:**

**ESR7**

**Computational characterisation, classification and deconvolution of myeloid regulatory cells**

<table>
<thead>
<tr>
<th>Host Institution</th>
<th>University of Regensburg, Germany</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Supervisor</td>
<td>Prof. REHLI, Michael - Prof. SPANG, Rainer</td>
</tr>
<tr>
<td>Email address</td>
<td><a href="mailto:michael.rehli@ukr.de">michael.rehli@ukr.de</a> - <a href="mailto:rainer.spang@ukr.de">rainer.spang@ukr.de</a></td>
</tr>
<tr>
<td>Planned duration</td>
<td>36 months</td>
</tr>
<tr>
<td>Subject Area</td>
<td>Computational Biology; Transcriptomics</td>
</tr>
</tbody>
</table>

**Introduction:** The distinctive tolerogenic signatures of MRC (as well as the signals required to induce and maintain them) are poorly understood, as are the fate and phenotypic stability of adoptively transferred cells in vivo. This predominantly computational project is concerned with **improving our understanding of differentiation routes, transcriptional and epigenetic features of MRCs** in vitro, as well as their adaptation in vivo to optimize tolerogenic cell products.

**Aims:**

**A1:** To devise computational methodology for the quantification and molecular characterization of MRC subsets in transcriptome or epigenome profiles from bulk samples such as blood or tissue. We will build on established deconvolution methods such as Cyber Sort and our in-house adaptive deconvolution algorithm based on loss-function learning. The method will be applied to public and consortium data.

**A2:** Modelling myeloid differentiation both in vitro and in vivo from transcriptome and epigenetic data to unravel regulatory networks, co-expression modules and corresponding pathways important for tolerogenicity of myeloid cell products. SB considers the implementation risk of this project is low because all required data are public or already shared.

**Expected Results:**

**R1a:** Novel deconvolution algorithms for an improved quantification of regulatory immune cells in bulk samples will be developed and implemented. The method will be open source and freely available to the scientific community. **R1b:** Annotating of existing bulk profile data sets from transcriptomics and epigenomics resources such as TCGA with computationally estimated immune cell composition. These will be made freely available in web applications and in portable containerized data warehouses that we will develop using the in-house LYRA system. **R2a:** Identification of latent factors that drive myeloid differentiation in cell therapy settings. These factors will inform the deconvolution models and guide their learning phase. **R2b:** Identification of signaling and regulatory pathways controlling tolerogenic features of cell products and computational prediction of candidate drugs that may improve the phenotypic stability or tolerogenic functions.

**Planned secondment:** The ESR will undertake a 2-month secondment at Miltenyi Biotec to expand their knowledge of management and analysis of immune cell-related NGS data.

**Enrolment in Doctoral degree(s):** University of Regensburg

**Project-specific selection criteria:** Degree in Mathematics, Computer Science, Physics or other project-relevant subject.


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860003
**ESR8**

**Development of Pharmaceutical Release Processes for DC-based Therapy**

<table>
<thead>
<tr>
<th><strong>Host Institution</strong></th>
<th>Cimaas BV, The Netherlands</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Supervisor</strong></td>
<td>Prof. GERMERAAD, Wilfred</td>
</tr>
<tr>
<td><strong>Email address</strong></td>
<td><a href="mailto:w.germeraad@cimaas.com">w.germeraad@cimaas.com</a></td>
</tr>
<tr>
<td><strong>Planned duration</strong></td>
<td>48 months</td>
</tr>
<tr>
<td><strong>Subject Area</strong></td>
<td>GMP Manufacturing; Quality Control; Cellular Immunology</td>
</tr>
</tbody>
</table>

**Introduction:** In order to ensure safety and clinical efficacy, stringent criteria for the identity, purity, potency, sterility and stability of therapeutic cell-based products must be established, implemented and validated as part of sterile pharmaceutical manufacturing processes. Cimaas specializes in manufacture of myeloid cell-based therapies using fully-closed, automated systems. In particular, CIM has developed innovative, GMP-compliant approaches for mRNA transfection of monocyte-derived cells. This project concerns integration of cutting-edge assays of regulatory macrophage (Mreg) and DC phenotype and function into semi-automated, fully closed manufacturing procedures to deliver robust, informative, scalable and cost-effective quality-control tests for process intermediates and cell products. Current QC protocols involve open handling steps but through this project, Cimaas aims to establish automated assays connected into a closed system workflow.

**Aims:**

**A1a:** To assimilate and adapt novel assays for myeloid cell phenotype and function that provide a minimal adequate profile of a cell product’s identity, potency and stability in the shortest time. **A1b:** To define a uniform set of release criteria in MRC-based therapies. **A2:** To participate in development of a final formulation of a frozen DC-based product that is free of animal components. **A3:** To characterize the MHC class II peptide presentation profile by mRNA electroporated DC. This project exemplifies how INsTRuCT can accelerate innovation in MRC-based therapy through commercial adoption of basic scientific discoveries. Cimaas already exchanged know-how with SQ, UA, UHREG and OSR. Further collaborations are anticipated with UNEW, Miltenyi and IGTP. SB has minimized project implementation risks through detailed planning of collaborations and ensuring sufficient redundancy in scientific deliverables.

**Expected Results:**

**R1:** Implementation and validation of QC assays for myeloid cell products within automated, closed manufacturing systems, including release testing for identity, purity, potency, sterility and stability. **R2:** Approval for an end-to-end sterile manufacturing process that can be used to produce component-free, frozen Mreg- and DC-based products with high viability and functionality after thawing. **R3:** Profiling of peptides in MHCII molecules expressed by mRNA electroporated DC.

**Planned secondment:** The ESR will undertake a 2-month secondment at Sanquin to master DC-CD4 T cell co-cultures and optimized release assays (ie. MHC-II multimer analyses) to develop antigen-specific release assays for electroporated DC.

**Enrolment in Doctoral degree(s):** University of Maastricht

**Project-specific selection criteria:** Strong background in Immunology; Interest in product development; main competencies: flexibility, creativity, can-do mentality

**Recommended reading:**

**ESR9**

**Personalized MRC-based therapy: innovative strategies to improve efficacy**

<table>
<thead>
<tr>
<th>Host Institution</th>
<th>King's College London, United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Supervisor</td>
<td>Prof. SANCHEZ FUEYO, Alberto - Prof. LOMBARDI, Giovanna</td>
</tr>
<tr>
<td>Email address</td>
<td><a href="mailto:sanchez_fueyo@kcl.ac.uk">sanchez_fueyo@kcl.ac.uk</a> - <a href="mailto:giovanna.lombardi@kcl.ac.uk">giovanna.lombardi@kcl.ac.uk</a></td>
</tr>
<tr>
<td>Planned duration</td>
<td>36 months</td>
</tr>
<tr>
<td>Subject Area</td>
<td>Computational Biology; Personalized Medicine</td>
</tr>
</tbody>
</table>

**Introduction:** We propose to create a highly personalised approach based on surrogate immunological biomarkers to assess tolerance induction in order to direct treatment with MRC-based therapies according to patients’ individual needs.

**Aims:**

**A1:** To perform sequential high-throughput phenotypic analysis of peripheral blood leucocytes from liver transplant recipients performing immunosuppression withdrawal to achieve tolerance by CyTOF, RNASEq and epigenetic landscaping (LIFT trial, >100 patients enrolled and centralized by KCL). **A2:** To evaluate antigen-specific responses in the same patients using in vitro functional assays, as well as profiling TCR repertoires of Tregs and effector T cells. **A3:** To correlate the distribution of antigen-specific effector and regulatory T cells based on TCR sequencing with peptide-specific MHC II tetramer staining in flow cytometry. **A4:** To develop bioinformatic tools to integrate phenotypic, transcriptional and epigenetic patterns in order to evaluate the function and stability of mixed leucocyte populations. **A5:** To apply the designed tolerogenic signatures and specific immune cell characterization methods to evaluate and compare the immunological effects of MRC-based and Treg-based therapies in liver (ThRIL, LITE studies at our center) and kidney transplant recipients (archived samples from UHREG, UN-CRTI).

**Expected Results:**

**R1:** The immunomonitoring techniques established and validated on clinical trials will provide new tools to study immunological mechanism of tolerance, monitor disease progression, evaluate therapeutic effect, stratify candidates for MRC-based immunotherapy, and serve as prognostic markers of clinical outcome. **R2:** The implementation of bioinformatic platforms to improve the identification and characterization of regulatory and effector cells in complex multicellular samples, such as peripheral blood or biopsies, will identify novel biomarkers that can be developed as innovative clinical assays.

**Planned secondment:** An intersectoral secondment of 5-months to UCB Pharma is planned to provide the student with experience in market-driven biomarker research and to pursue aims A1 and A2.

**Enrolment in Doctoral degree(s):** King’s College London

**Project-specific selection criteria:** Desirable experience in molecular biology laboratory, preferable experience with techniques, such as Western Blotting, flow cytometry and qPCR. Knowledge of Immunology and in particular innate immunity preferable.

ESR10
Development and validation of antigen-specific assays for T and B cell responses following tolerance-inducing treatments with MRC-based therapies

<table>
<thead>
<tr>
<th>Host Institution</th>
<th>Sanquin Blood Supply and University of Amsterdam, The Netherlands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Supervisor</td>
<td>Prof. ten BRINKE, Anja - Prof. van HAM, Marieke</td>
</tr>
<tr>
<td>Email address</td>
<td><a href="mailto:a.tenbrinke@sanquin.nl">a.tenbrinke@sanquin.nl</a> - <a href="mailto:m.vanham@sanquin.nl">m.vanham@sanquin.nl</a></td>
</tr>
<tr>
<td>Planned duration</td>
<td>48 months</td>
</tr>
<tr>
<td>Subject Area</td>
<td>Cellular Immunology; Personalized Medicine</td>
</tr>
</tbody>
</table>

**Introduction:** This project aims to develop versatile peptide-specific MHCII tetramers to increase the number of specific T cell responses that can be analysed in patients with autoimmune diseases. In addition, we will perform antigen-specific T cell receptor (TCR), B cell receptor (BCR) and single cell RNA sequencing. These innovations will allow more complete interpretation of the immunological and therapeutic impact of MRC-based therapies in clinical trials.

**Aims:**
- **A1:** To establish standardised and validated immunomonitoring assays of CD4+ T cell responses against disease-relevant antigens that will be useful for evaluating the efficacy and safety of tolerance-inducing MRC-based therapies.
- **A2:** To assess the effects of MRC-based therapies on auto-, allo- or recall- Ag-specific CD4+ T cell responses using new or archived samples from consortium partners.
- **A3:** To develop standardised and validated assays to measure Ag-specific memory B cell and Ag-specific antibody formation. Analysis of patient cohorts not treated with MRC-based therapies might be performed as an alternative proof-of-concept.

**Expected Results:**
- **R1:** Standardization of proliferation dye-based assay to monitor ag-specific CD4+ T cell responses.
- **R2:** Up-scaling production of patient and antigen-tailored in house developed peptide-exchangeable MHCII tetramers.
- **R3:** Establishment of an assay to measure antigen-specific antibody and memory B cell responses.
- **R4:** Analysis of Ag-specific T and B cell responses before, during and after tolerance inducing cell therapy to study safety and efficacy and to obtain insights in the mode-of-action of the applied immunotherapy.

**Planned secondment:**
(1) An international 2-month secondment is planned to the lab of Dr. Nathalie Cools (Belgium) to provide the ESR with training in METC application and clinical trial immunomonitoring, as well as logistics of sample retrieval and clinical database registration during conduct of clinical trials.
(2) An international, 2-month industrial secondment to Miltenyi (Germany) will support preclinical development of commercially viable antigen-specific immune monitoring assays.

**Enrolment in Doctoral degree(s):** University of Amsterdam, the Netherlands

**Project-specific selection criteria:**
- [1] A Master degree in Biomedical Sciences or a similar education level.
- [2] Knowledge of Immunology is required and a proven track record in research in cellular immunology is a prerequisite.
- [3] Team player with good communication skills.

**Recommended reading:**

www.instruct-h2020.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860003
**ESR11**  
**Development of an affordable & scalable process for toIDC manufacturing**

<table>
<thead>
<tr>
<th>Host Institution</th>
<th>University of Antwerp, Belgium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Supervisor</td>
<td>Prof. COOLS, Nathalie</td>
</tr>
<tr>
<td>Email address</td>
<td><a href="mailto:nathalie.cools@uza.be">nathalie.cools@uza.be</a></td>
</tr>
<tr>
<td>Planned duration</td>
<td>48 months</td>
</tr>
<tr>
<td>Subject Area</td>
<td>GMP Manufacturing; Quality Control; Cellular Immunology</td>
</tr>
</tbody>
</table>

**Introduction:** Development of MRC-based products has been restricted by their cost and complexity. This is especially true when a unique batch is manufactured for each patient using labor-intensive, multiple-step processes. Successful future commercialization of cell-based, patient-specific products will require innovative solutions to unique manufacturing challenges and constraints; critically, any technological solutions will have to be affordable, reliable and not introduce new process-related risks. In this project, we aim to unlock new opportunities for the development of commercially viable and safe cell-based treatments by co-development of next generation technologies to facilitate lean, cost-effective manufacturing of MRC products, in particular toIDC. In collaboration with Antleron, an end-to-end closed and automated cell culture system will be developed that contains all features essential for safe production of cell therapies: precise control over temperature and fluid flow, mixing and cell seeding capability, internal refrigeration, light protection, various sterile access points to verify cell differentiation, biosensors to monitor cell performance and automated computer-controlled record keeping.

**Aims:**  
A1: To identify biological factors contributing to the optimal micro-environment for MRC generation that will allow redesign of MRC manufacturing processes to ensure product consistency and quality.  
A2: To engineer 4D environments for MRC generation that increase process reproducibility and robustness, and optimize roll-out of MRC products to the market.

**Expected Results:**  
R1: Novel biological insights into the differentiation process of toIDC and other MRC types, such as the influence of environment factors (e.g. cell density, growth surface material, pH, dissolved oxygen and shear stress) affect quality-control measures and potency of MRC-based products. This information will be invaluable for the parallel development of a scalable and automated process.  
R2: Development of an R&D scale proof-of-concept bioreactor-driven toIDC differentiation process with integrated up- and down-stream unit operations, and built-in quality control measures to monitor critical cell culture parameters.  
R3: Mapping of cost of goods in order to transition from R&D scale to an industrialized process.

**Secondments:**  
(1) An intersectoral secondment of 6 months to Antleron is planned to provide the ESR with training in cell growth micro-environments and experience in designing scale-up and scale-out procedures in GMP conditions. Aim 2 is dependent upon this secondment.  
(2) An international, intersectoral secondment of 2 months to CiMaas BV will provide the ESR with a market-oriented perspective of manufacturing and roll-out of MRC-based products.

**Enrolment in Doctoral degree(s):** University of Antwerp

**Project-specific selection criteria:** Master's degree in Bio(medical) Engineering, Biotechnology, Mechanical Engineering or equivalent qualifications. Practical laboratory experience preferred.

**Recommended reading:**  
## ESR12
### Metabolic Programming of Human Monocyte Differentiation

<table>
<thead>
<tr>
<th>Host Institution</th>
<th>Miltenyi Biotec BV &amp; Co. KG, Bergisch Gladbach, Germany</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Supervisor</td>
<td>Dr. KOLLET, Jutta</td>
</tr>
<tr>
<td>Email address</td>
<td><a href="mailto:jutta.kollet@miltenyibiotec.de">jutta.kollet@miltenyibiotec.de</a></td>
</tr>
<tr>
<td>Planned duration</td>
<td>36 months</td>
</tr>
<tr>
<td>Subject Area</td>
<td>Computational Biology; Image Analysis</td>
</tr>
</tbody>
</table>

**Introduction:** It is critical to understand differences between myeloid cell populations in the context their surrounding tissue microenvironments. This project will identify and systematically characterize the MRC networks in tissues through development of computational methods to analyze multiparametric immunofluorescence image data (MACSimaTM technology). The composition and spatial distribution of MRC subsets in tissues will be classified using machine learning on a knowledge database.

**Aims:**

- **A1:** To apply model-based machine learning algorithms on multiparametric immunofluorescence image data of pancreatic cancer sections to identify and characterize the tolerogenic myeloid regulatory network.  
- **A2:** To generate experimental image datasets from unrelated tissue sections to validate and optimize the initially generated classifier.  
- **A3:** To optimize predictions and analysis tools by inclusion of self-learning components.

**Expected Results:**

- **R1:** The phenotype and spatial network of MRC in tissues (eg. tumour, transplant) will be characterized; thereby phenotypically distinct subpopulations of MRC will be identified.  
- **R2:** Understanding of the correlation of transcriptome and proteome data and of the function of cell types will be obtained from collaborations with UHREG. This is particularly important, since public NGS datasets are frequently used for biomarker/target discovery.  
- **R3:** Data-driven marker collections (‘self-learning’ algorithms will automatically update a data base) will be used for identification and prediction of cell composition.  
- **R4:** Optimization and commercialization of antibody panels for kits and diagnostics for use in identifying or isolating MRC subsets using the newly developed software tools.  
- **R5:** Software for automated annotation and cell type classification in immunofluorescence images and novel visualization methods for multiparametric datasets will be established.

**Planned secondment:** A 2-month secondment to the labs of Professors Spang and Rehli is planned to train the ESR in analyzing different types of ‘Big Data’ in order to make correlations with imaging-based proteome data.

**Enrolment in Doctoral degree(s):** University of Regensburg

**Project-specific selection criteria:** Degree in Bioinformatics, Computer Science, or Biology with project-relevant subject.


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860003
**ESR13**  
**Genes & pathways associated with the tolerogenic capacity of tolDC-VitD3**

<table>
<thead>
<tr>
<th>Host Institution</th>
<th>Institute of the Germans Trias i Pujol Foundation, Barcelona, Spain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Supervisor</td>
<td>Prof. MARTINEZ CACERES, Eva</td>
</tr>
<tr>
<td>Email address</td>
<td><a href="mailto:emmartinez.germanstrias@gencat.cat">emmartinez.germanstrias@gencat.cat</a></td>
</tr>
<tr>
<td>Planned duration</td>
<td>36 months</td>
</tr>
<tr>
<td>Subject Area</td>
<td>Molecular &amp; Cellular Immunology; Translational Research</td>
</tr>
</tbody>
</table>

**Introduction:** Our research group has developed an autologous, antigen-specific cell-based therapeutic product for treatment of multiple sclerosis (MS) known as, “tolDC-VitD3.” We are now conducting a **Phase-I dose-escalation** clinical trial of **tolDC-VitD3 therapy in patients with MS** (EUDRA CT 2015-003541-26). 12 patients with active MS will receive tolDC-VitD3 by intranodal injection, followed by a 24-month observation and immune monitoring period. This project investigates pharmacodynamic effects of tolDC-VitD3 treatment in patients enrolled in this clinical trial.

**Aims:**

**A1:** To perform silencing /downmodulation of candidate molecules on cells at different stages during the differentiation of monocytes into tol-DC-vitD3 or stimulatory DC with the aim of identifying transcriptional regulatory factors (TFs) governing the tolerogenic DC programme.  
**A2:** To analyse the contribution of TFs identified in A1 to overall tolerogenic phenotype human tolDC-vitD3 using established co-culture assays looking at T cell differentiation and effector functions.  
**A3:** To analyse the functional effect of tolDC VitD3 on peripheral blood T cells of multiple sclerosis patients compared to those of healthy donors.  
**A4:** To examine antigen-specific T and B cell responses of MS patients in the tolDC-VitD3 clinical trial (before, during and after cell therapy) as a low-risk project.

**Expected Results:**

**R1:** New potential therapeutic targets involved in tolerance induction by tolDC-VitD3 will be identified through our in vitro experiments and analysis of patient samples.  
**R2:** Strategies will be developed to support tolDC-VitD3 treatment using drugs that interact with immunological networks affected by tolDC-VitD3 administration.  
**R3:** Novel clinical indications for tolDC-VitD3 will be investigated, especially other neuroinflammatory diseases and solid organ transplantation.

**Planned secondment:**

1. An international secondment of 2-months to Prof. van Ham is planned to undertake collaborative work on aim A4.  
2. A 2-month intersectoral secondment to Aniling is planned.  
3. An intersectoral secondment of 2-months will be spent in the academic department of Prof. Ochando where the student will learn about Transplant Immunology and solid organ transplant models.

**Enrolment in Doctoral degree(s):** Autonomous University of Barcelona

**Recommended reading:**

ESR14
Therapeutic Targeting of Mreg - T cell Interactions

<table>
<thead>
<tr>
<th>Host Institution</th>
<th>University Hospital Regensburg, Germany</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Supervisor</td>
<td>Dr. HUTCHINSON, James Alexander</td>
</tr>
<tr>
<td>Email address</td>
<td><a href="mailto:james.hutchinson@ukr.de">james.hutchinson@ukr.de</a></td>
</tr>
<tr>
<td>Planned duration</td>
<td>36 months</td>
</tr>
<tr>
<td>Subject Area</td>
<td>Molecular &amp; Cellular Immunology; Immunopharmacology</td>
</tr>
</tbody>
</table>

**Introduction:** Administration of human regulatory macrophages (Mreg) has shown early clinical promise as an adjunct immunosuppressive cell-based therapy in solid organ transplantation. This project proposal addresses the hypothesis that recipient T cell immunity is actively regulated through direct allorecognition of donor-derived Mregs and conversion of naive CD4+ T cells to FoxP3+ induced regulatory T cells. A sensitive and rapid functional screening assay has been developed to measure Mreg-mediated conversion of naïve CD4+ to FoxP3+ iTregs (miTregs). We propose to use this in vitro assay system to define novel mechanisms contributing to generation, stabilization or expansion of miTregs.

**Aims:**

A1: To screen libraries of antibodies and small molecules for substances that affect miTreg generation using our established miTreg assay. A2: To investigate the contribution of Mreg-specific or miTreg-specific genes identified from previous transcriptional profiling studies to Mreg-induced Treg generation using gene-editing or -silencing techniques in our established assay system. A3: To investigate the pharmacological effects of substances identified by our screening assays in a human-into-mouse reconstitution model of human Mreg-driven allogeneic Treg conversion.

**Expected Results:** R1: Original basic scientific insights into the suppressor functions of Mregs, including identification of new suppressive mechanisms, will follow from the functional screening experiments; R2: agents that enhance or repress miTreg generation will be identified and their effects characterized; R3: New Mreg-specific mAbs and clinical tests will be developed.

**Planned secondment:** (1) An international, intersectoral secondment of 3 months to AstraZeneca will provide the ESR with an industrial perspective of drug screening and a broader view of pharmaceutical development.

**Enrolment in Doctoral degree(s):** University of Regensburg

**Project-specific selection criteria:** Practical experience of common techniques in Molecular Biology and Cellular Immunology.

**Recommended reading:** Riquelme, P. et al. TIGIT+ iTregs elicited by human regulatory macrophages control T cell immunity (2018) Nature Communications. 9, 2858. https://doi.org/10.1038/s41467-018-05167-8

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 860003

www.instruct-h2020.eu
# ESR15
## Route of delivery of tolerogenic dendritic cells

<table>
<thead>
<tr>
<th>Host Institution</th>
<th>University of Newcastle, United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Supervisor</td>
<td>Prof. ISAACS, John - Dr. HILKENS, Catharien</td>
</tr>
<tr>
<td>Email address</td>
<td><a href="mailto:john.isaacs@newcastle.ac.uk">john.isaacs@newcastle.ac.uk</a> - <a href="mailto:catharien.hilkens@newcastle.ac.uk">catharien.hilkens@newcastle.ac.uk</a></td>
</tr>
<tr>
<td>Planned duration</td>
<td>36 months</td>
</tr>
<tr>
<td>Subject Area</td>
<td>Cellular Immunology; Translational Research</td>
</tr>
</tbody>
</table>

**Introduction:** We have developed a robust, GMP-compatible process to generate stable tolDC from patients with rheumatoid arthritis (RA). We recently completed a phase I trial showing that tolDC administration into an inflamed knee joint is safe. Diminished synovial inflammation was observed in the knee joint of patients treated with the highest tolDC dose; however no systemic changes were observed, either in overall disease activity or immune markers in blood. RA is a systemic disease, so tolDC may be more effective if they migrated to secondary lymphoid tissue. Therefore, we need to know (i) where tolDC migrate to after injection and (ii) whether they modulate T cell responses systemically. The aim of this clinically orientated project is to develop and validate tools required for addressing these questions in on-going clinical studies.

**Aims:**

- **A1:** To assess the distribution of tolDC loaded with relevant citrullinated peptides (citP) injected via different routes into patients by 19F-magnetic resonance imaging (MRI);
- **A2:** To assess whether tolDC treatment modulates citP-specific T cell responses assayed by the use of MHCII-citP tetramers in collaboration with SQ.

**Expected Results:**

- **R1:** Determination of the sensitivity of detecting 19F-labelled tolDC by MRI;
- **R2:** Confirmation that 19F-labelling of tolDC does not affect their migratory ability and tolerogenic functions;
- **R3:** Establishment of an immunmonitoring protocol to assess functional properties (e.g. cytokine production, suppressive capability) of citP-specific T cells from RA patients. For this work we will make use of relevant citP-MHCII tetramers provided by our partners of the RTCure consortium and collaborations with ESR10.
- **R4:** Application of these immunmonitoring protocols to samples obtained from RA patients before and after tolDC administration.

**Enrolment in Doctoral degree(s):** Newcastle University

**Project-specific selection criteria:** Masters degree in a biological or biomedical science with laboratory experience in immunological techniques innate immunity preferable.

**Recommended reading:**


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860003.